Skip to Content
Discovering the causes of cancer and the means of prevention

Publications Search - Abstract View

Title: Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women.
Authors: Kemp TJ,  García-Piñeres A,  Falk RT,  Poncelet S,  Dessy F,  Giannini SL,  Rodriguez AC,  Porras C,  Herrero R,  Hildesheim A,  Pinto LA,  Costa Rica Vaccine Trial (CVT) Group
Journal: Vaccine
Date: 2008 Jul 4
Branches: MEB, CGR
PubMed ID: 18541349
PMC ID: PMC4131294
Abstract: Ideal methods to monitor HPV neutralizing antibodies induced by vaccination have not been established yet. Here, we evaluated systemic and cervical antibody levels induced by HPV16/18 AS04-adjuvanted vaccine (GlaxoSmithKline Biologicals) using a secreted alkaline phosphatase neutralization assay (SEAP-NA) and enzyme-linked immunosorbent assay (ELISA). Serum and cervical secretions from 50 vaccinated women were used to assess (1) overall assay reproducibility; (2) inter-assay and inter-specimen correlation; (3) correlations between month 1 and month 12 titers. Strong correlations between SEAP-NA and ELISA were observed (serum anti-HPV16/18, rho=0.91/0.85; cervix anti-HPV16/18, rho=0.84/0.89). Systemic and cervical antibody measures also correlated well (rho range: 0.64-0.75); except at mid-cycle (rho range: 0.28-0.65). Correlations between antibody levels at 1 and 12 months following the start of vaccination were poor (rho range: 0.16-0.38). In conclusion, HPV16/18 VLP-based ELISA is a reliable and valid method to monitor anti-HPV16/18 neutralizing potential for the first year following vaccination; however, additional studies will be required to better define the effects of the time on cycle and patterns of antibody response over time following vaccination.